Thursday, March 10th 2011
from 6.00PM to 9.00PM
Duane Morris LLP, One Market Plaza, Spear Tower, Suite 2200,
San Francisco, CA

GABA and FACCSF Life Science Committees have invited experts from industry, research and clinical research to discuss the most promising research and trends in Alzheimer’s treatment.

Alzheimer’s disease is the most common form of senile dementia. It has been estimated that 35.6 million people living with dementia worldwide in 2010, requiring 604 billion US dollar for treatment on multiple levels. The disease is typically associated with a slow but progressive loss of nerve cells and nerve cell contacts. Recent advancements in the study of Alzheimer’s disease brain function in mice has determined that neural stem cells injected into the brains of those mice help to rebuild neural connections and thereby improve cognitive function. GCSF (granulocyte colony stimulating factor) has been shown to reduce levels of a brain clogging specific protein (beta amyloid), while at the same time increasing new neuron development and nerve cell connections.

Speakers:

Prof. Dale Bredesen, Buck Institute
William F. Goure, Ph.D., Acumen Pharmaceuticals
James Trenor - Director of Neuroscience, Amgen

Registrations